StreetAlpha.app
Home › Stocks › ASND

Ascendis Pharma A (ASND)

Healthcare
$271.19
▼ −0.20%
LAST CLOSE · NOV 17

Ascendis Pharma develops rare disease treatments based on its TransCon technology, including YORVIPATH and SKYTROFA. It last closed at $271.19 on Nov 17, down 0.20% on the day. ASND reports earnings on Wed, Feb 10, 2027. The average 12-month price target from 15 analysts is $318.47 (+17.4% from the last close), with a high of $356.00 and a low of $273.00. Analyst consensus is Strong Buy, based on the latest ratings from 15 firms (14 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in ASND, 0% of them bullish and 100% bearish. In the past 30 days there were 8 dark pool prints totaling $9.8M, the largest $2.5M.

AI Auto Pilots
Is ASND in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
EUR 720.1M
+98.0% vs a year ago
Net income
−EUR 228.0M
−31.7% margin
Gross margin
86.8%
EUR 625.2M gross profit
Operating margin
−18.9%
−EUR 136.3M operating income
Balance sheet
Cash & equivalents
EUR 616.0M
At Dec 31
Debt
EUR 720.3M
At Dec 31
Shareholder equity
−EUR 162.8M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: EUR 7.8MEUR 7.8MFY2021FY2022: EUR 51.2MEUR 51.2MFY2022FY2023: EUR 266.7MEUR 266.7MFY2023FY2024: EUR 363.6MEUR 363.6MFY2024FY2025: EUR 720.1MEUR 720.1MFY2025

From ASND's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Feb 11). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.

Next report
Feb 10
2027 · Time not announced
Consensus EPS forecast
$1.45
$504.1M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 15 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
15firms
14 Buy1 Hold0 Sell
Each firm's latest rating on ASND in the past 90 days
Average 12-month target
$318.47
▲ 17.4% upside

Based on 15 analysts who set a price target on ASND in the past 90 days. The average target is $318.47, with a high of $356.00 and a low of $273.00, compared with the last close of $271.19.

Low $273.00Avg $318.47High $356.00
Blue marker: last close $271.19
Highest target$356.00
Average target$318.47
Lowest target$273.00
Latest rating changes
BarclaysTarget raised
Nov 16Buy$329 → $341
UBSTarget raised
Nov 13Buy$269 → $315
TD CowenTarget raised
Nov 13Buy$341 → $352
Evercore ISI GroupMaintained
Nov 13Buy$356
Canaccord GenuityMaintained
Nov 13Hold$274
DateFirmActionRatingPrice target
Nov 16BarclaysTarget raisedBuy$329 → $341
Nov 13UBSTarget raisedBuy$269 → $315
Nov 13TD CowenTarget raisedBuy$341 → $352
Nov 13Evercore ISI GroupMaintainedBuy$356
Nov 13Canaccord GenuityMaintainedHold$274
Loading…

Technical Analysis

ASND · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought

The stock is 6% above its 20 day and 10% above its 50 day average. It is 11% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 69), near overbought. The nearest support is the Pivot at $267.96, and the nearest resistance the swing high (Jun 25) at $271.89.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityNormal, 2.7%/day
Key levels
$282.1552 week high+4.0%
$274.94Pivot R1+1.4%
$271.89Swing high (Jun 25)+0.3%
$271.19Last close
$267.96Pivot−1.2%
$264.20Pivot S1−2.6%
$254.9220 day average−6.0%
$250.23100 day average−7.7%
$248.34Swing low (Nov 4)−8.4%
$242.7150 day average−10.5%
$240.32200 day average−11.4%
$188.0852 week low−30.6%
Indicators
RSI (14)68.96Strong, overbought above 70Neutral
MACD8.52Above its signal lineBullish
Stochastic82.5Near the top of its rangeOverbought
ADX (14)39.5Trending up
Williams %R-24.4Oversold below −80, overbought above −20Neutral
CCI (20)120.2Oversold below −100, overbought above 100Overbought
Rate of change+8.4%Change over 10 sessionsBullish
ATR (14)$7.34Typical daily range, 2.7% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for ASND

What happened before

See how ASND did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ASND usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ASND has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
0
0%
Bearish
2
100%
Date span
Sep 15 – Oct 7
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
8
Notional
$9.8M
Largest print
$2.5M
Loading…

ASND Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲222 buying vs 145 selling
  • ▲Shares held by funds +2.1%
  • ▲Funds holding +34
  • ▼Superinvestors: 1 added, 3 cut
  • ▼Put/call 0.14 to 0.15
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding350316+10.8%
In funds' top 101613+23.1%
Held by funds–––
New / increased83 / 139296 / 7−26.7%
Reduced / sold out97 / 484 / 267−46.5%
Put/call ratio0.150.14+7.2%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ASND institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ASND is in one of them and how their past ASND trades turned out.

ASND in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ASND in an article yet. Here's the latest on the wider market.

ASND Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Nov 7
Who traded ASND · since 2018
Latest 3 filings
$1K – $15KTraded Oct 5, 2018Filed Nov 7, 2018
$1K – $15KTraded Aug 6, 2018Filed Sep 29, 2018
$1K – $15KTraded Jul 12, 2018Filed Sep 29, 2018
PersonTypeAmountTradedFiledDelay
Gary PalmerR · ALSell$1K – $15KOct 5, 2018Nov 7, 201833 d
Gary PalmerR · ALBuy$1K – $15KAug 6, 2018Sep 29, 201854 d
Gary PalmerR · ALBuy$1K – $15KJul 12, 2018Sep 29, 201879 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Ascendis Pharma A

Ascendis Pharma is a biopharmaceutical company based in Hellerup, Denmark. It develops medicines built on its TransCon technology, with a focus on rare endocrine conditions. Its approved products are YORVIPATH, for adults with hypoparathyroidism, and SKYTROFA, for people with growth hormone deficiency. The company also has product candidates in development for other growth disorders and in oncology, and it works with partners in Japan and China. Its customers are patients and the healthcare providers who prescribe its treatments.

Headquarters
Hellerup
Founded
2007